Annovis Bio Inc (ANVS)
NYSEHealth CareBiotechnologySnapshot 2026-09-09
$1.22-6.15%
Close 2026-09-09 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Operating losses remain near negative $18 million: metric not reported.
Annovis Bio focuses on managing operating losses near negative $18 million in 2026-Q1. The company aims to control cash burn around negative $9 million in the same quarter. Progress in clinical trials could drive future growth. Debt issuances provide needed capital to support development.
Operating losses worsened from negative $6.3 million in 2025-Q1 to negative $18 million in 2026-Q1. Cash from operations remains negative near $9 million. Earnings estimates show continued losses with EPS around negative $1.8 for 2026. Recent share dilution and management turnover add risks.
The market reflects a selling-off environment with no clear consensus on revenue or earnings growth. The share price likely prices in ongoing losses and dilution risks. Our view differs by focusing on the potential for clinical progress and cost control to stabilize losses.
Breaks if: cash burn worsens beyond negative $9 million next quarter
Control operating expenses and cash burn while advancing clinical programs, despite ongoing net losses.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the biotech sector. The company is in a clinical development phase, focusing on Alzheimer's treatments, but faces high risks due to its loss-making status and recent weak financial performance.
The market appears to have priced in significant uncertainty given the company's ongoing losses and the mixed signals from recent earnings reports. There is an expectation for volatility, especially if guidance is cut or if broader economic conditions worsen.
Management is making progress in clinical trials, particularly with enrollment in a pivotal Phase 3 trial. However, the company is struggling to manage its operating losses and cash burn, which may limit its financial stability in the near term.
The long-term thesis hinges on the outcomes of clinical trials and the ability to manage cash flow effectively. Additionally, the performance of larger healthcare peers could influence sentiment and momentum in the sector.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement. The company is advancing its clinical development programs for Alzheimer's. There are no new threats to the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management has stated managing operating losses and cash burn as a priority in 8 consecutive quarters from 2024-Q3 through 2026-Q2. Net losses increased from $5.9M in 2024-Q4 to $14.8M in 2026-Q2, while cash reserves slightly declined from $19.5M to $18.7M over the same period. The trajectory shows ongoing losses and cash burn consistent with clinical-stage biotech operations, indicating limited progress in reducing net losses so far.
“Net loss of $14.8 million and operating loss of $14.4 million for the quarter ended June 30, 2026.”
“Reported net loss of $17.6 million and operating loss of $18.0 million for the quarter ended March 31, 2026.”
“Net loss of $9.8 million and operating loss of $9.7 million for the quarter ended December 31, 2025.”
“Net loss of $7.3 million and operating loss of $7.4 million for the quarter ended September 30, 2025.”
“Net loss of $6.2 million and operating loss of $6.3 million for the quarter ended June 30, 2025.”
“Net loss of $5.5 million and operating loss of $6.3 million for the quarter ended March 31, 2025.”
“Net loss of $5.9 million and operating loss of $6.7 million for the quarter ended December 31, 2024.”
“Net loss of $12.6 million and operating loss of $4.4 million for the quarter ended September 30, 2024.”
Breaks if: clinical development stalls or regresses over next 12 months
Complete pivotal Phase 3 trials for Alzheimer's and Parkinson's diseases with key enrollment and data readout milestones.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2. The pivotal Phase 3 Alzheimer's trial enrollment exceeded the original target, reaching 850 patients versus 760 planned. The company expects symptomatic data readout in Q1 2027 and disease-modifying data in Q1 2028. Management is delivering on enrollment milestones and progressing clinical development as planned.
“Pivotal Phase 3 AD trial fully enrolled with 850 patients, exceeding original projections.”
“Full enrollment of pivotal Phase 3 trial with 850 patients; symptomatic data readout expected Q1 2027.”
“Announced proposed public offering to fund continued clinical development of buntanetap in Phase 3 study for AD.”
Breaks if: operating losses worsen beyond negative $18 million next quarter
Control operating expenses and cash burn while advancing clinical programs, despite ongoing net losses.
Management has stated managing operating losses and cash burn as a priority in 8 consecutive quarters from 2024-Q3 through 2026-Q2. Net losses increased from $5.9M in 2024-Q4 to $14.8M in 2026-Q2, while cash reserves slightly declined from $19.5M to $18.7M over the same period. The trajectory shows ongoing losses and cash burn consistent with clinical-stage biotech operations, indicating limited progress in reducing net losses so far.
“Net loss of $14.8 million and operating loss of $14.4 million for the quarter ended June 30, 2026.”
“Reported net loss of $17.6 million and operating loss of $18.0 million for the quarter ended March 31, 2026.”
“Net loss of $9.8 million and operating loss of $9.7 million for the quarter ended December 31, 2025.”
“Net loss of $7.3 million and operating loss of $7.4 million for the quarter ended September 30, 2025.”
“Net loss of $6.2 million and operating loss of $6.3 million for the quarter ended June 30, 2025.”
“Net loss of $5.5 million and operating loss of $6.3 million for the quarter ended March 31, 2025.”
“Net loss of $5.9 million and operating loss of $6.7 million for the quarter ended December 31, 2024.”
Over the next 1 to 3 years, ANVS faces significant challenges but also opportunities tied to its clinical developments. The situation warrants careful observation. Not investment advice.
“Net loss of $12.6 million and operating loss of $4.4 million for the quarter ended September 30, 2024.”